In our previous studies, we observed the effect of blocking the 20-HETE pathway with HPßCD-HET0016, a highly selective inhibitor, which involves the CYP4A and CYP4F families in inhibiting tumor angiogenesis, proliferation, migration, and regulation, in human breast cancer and glioma models [8,9]. This evidence concerns the gene CYP4F3 and breast cancer.